111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024 02:05 ET | Boehringer Ingelheim
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...
anamar-logo.png
AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis
February 05, 2024 03:00 ET | AnaMar AB
LUND, Sweden, Feb. 05, 2024 (GLOBE NEWSWIRE) -- AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024 08:05 ET | Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
January 22, 2024 07:00 ET | Sagimet Biosciences Inc.
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis Primary efficacy...
Logo.png
GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis
December 14, 2023 03:29 ET | GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out-licensing...
Engitix_Logo_RGB.jpg
Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer
September 05, 2023 07:00 ET | Engitix Therapeutics
LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary...
Logo.png
Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe
June 23, 2023 08:01 ET | Ocean Biomedical, Inc.
Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...
tb_pressreleaselogo.png
Taglich Brothers Initiates Coverage of Ocean Biomedical, Inc.
May 31, 2023 09:30 ET | Taglich Brothers Inc
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of Ocean Biomedical, Inc. (NASDAQ: OCEA). Ocean Biomedical, Inc. headquartered in...
anamar-logo.png
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
May 23, 2023 03:00 ET | AnaMar AB
First-in-class, peripheral serotonin (5-HT2B) receptor antagonist being developed as a highly selective, oral, anti-fibrotic medicine for skin and lung disorders LUND, Sweden, May 23, 2023 (GLOBE...
Engitix_Logo_RGB.jpg
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
May 09, 2023 04:00 ET | Engitix Therapeutics
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...